Anti-tumour effects of TRAIL-expressing human placental derived mesenchymal stem cells with curcumin-loaded chitosan nanoparticles in a mice model of triple negative breast cancer

References

• World Health Organization. Global status report on noncommunicable diseases 2010. Geneva: World Health Organization; 2011.
   Google Scholar
• Ferlay J, Soerjomataram I, Ervik M. GLOBOCAN, cancer incidence and mortality worldwide: IARC cancer base no. 11 [Internet]. Lyon (France): International Agency for Research on Cancer; 2013.
   Google Scholar
• Anders CK, Carey LA. Biology, metastatic patterns, and treatment of patients with triple-negative breast cancer. Clin Breast Cancer. 2009;9:S73–S81.
   PubMed Web of Science ®Google Scholar
• Hurvitz S, Mead M. Triple-negative breast cancer: advancements in characterization and treatment approach. Curr Opin Obstetr Gynecol. 2015;28:1–69.
   Web of Science ®Google Scholar
• Wu GS. TRAIL as a target in anti-cancer therapy. Cancer Lett. 2009;285:1–5.
   PubMed Web of Science ®Google Scholar
• Ashkenazi A, Holland P, Eckhardt SG. Ligand-based targeting of apoptosis in cancer: the potential of recombinant human apoptosis ligand 2/tumor necrosis factor–related apoptosis-inducing ligand (rhApo2L/TRAIL). JCO. 2008;26:3621–3630.
   PubMed Web of Science ®Google Scholar
• Stuckey DW, Shah K. TRAIL on trial: preclinical advances in cancer therapy. Trends Mol Med. 2013;19:685–694.
   PubMed Web of Science ®Google Scholar
• De Miguel D, Gallego-Lleyda A, Ayuso JM, et al. High-order TRAIL oligomer formation in TRAIL-coated lipid nanoparticles enhances DR5 cross-linking and increases antitumour effect against colon cancer. Cancer Lett. 2016;383:250–260.
   PubMed Web of Science ®Google Scholar
• An D, Kim K, Kim J. Microfluidic system based high throughput drug screening system for curcumin/TRAIL combinational chemotherapy in human prostate cancer PC3 cells. Biomol Ther. 2014;22:355.
   PubMed Web of Science ®Google Scholar
• Naksuriya O, Okonogi S, Schiffelers RM, et al. Curcumin nanoformulations: a review of pharmaceutical properties and preclinical studies and clinical data related to cancer treatment. Biomaterials. 2014;35:3365–3383.
   PubMed Web of Science ®Google Scholar
• Park S, Cho DH, Andera L, et al. Curcumin enhances TRAIL-induced apoptosis of breast cancer cells by regulating apoptosis-related proteins. Mol Cell Biochem. 2013;383:39–48.
   PubMed Web of Science ®Google Scholar
• Jung EM, Lim JH, Lee TJ, et al. Curcumin sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-induced apoptosis through reactive oxygen species-mediated upregulation of death receptor 5 (DR5). Carcinogenesis. 2005;26:1905–1913.
   PubMed Web of Science ®Google Scholar
• Bieback K, Kern S, Kocaömer A, et al. Comparing mesenchymal stromal cells from different human tissues: bone marrow, adipose tissue and umbilical cord blood. Bio-Med Mater Eng. 2008;18:71–76.
   PubMed Web of Science ®Google Scholar
• Yen BL, Huang HI, Chien CC, et al. Isolation of multipotent cells from human term placenta. Stem Cells. 2005;23:3–9.
   PubMed Web of Science ®Google Scholar
• Barry FP, Murphy JM. Mesenchymal stem cells: clinical applications and biological characterization. Int J Biochem Cell Biol. 2004;36:568–584.
   PubMed Web of Science ®Google Scholar
• Chulpanova DS, Kitaeva KV, Tazetdinova LG, et al. Application of mesenchymal stem cells for therapeutic agent delivery in anti-tumor treatment. Front Pharmacol. 2018;9:259.
   PubMed Web of Science ®Google Scholar
• Xie C, Yang Z, Suo Y, et al. Systemically infused mesenchymal stem cells show different homing profiles in healthy and tumor mouse models. Stem Cells Transl Med. 2017;6:1120–1131.
   PubMed Web of Science ®Google Scholar
• Gholizadeh-Ghaleh Aziz S, Fathi E, Rahmati-Yamchi M, et al. An update clinical application of amniotic fluid-derived stem cells (AFSCs) in cancer cell therapy and tissue engineering. Artif Cells Nanomed Biotechnol. 2017;45:765–774.
   PubMed Web of Science ®Google Scholar
• Reagan MR, Seib FP, McMillin DW, et al. Stem cell implants for cancer therapy: TRAIL-expressing mesenchymal stem cells target cancer cells in situ. J Breast Cancer. 2012;15:273–282.
   PubMed Web of Science ®Google Scholar
• Kaplan HG, Malmgren JA. Impact of triple negative phenotype on breast cancer prognosis. Breast J. 2008;14:456–463.
   PubMed Web of Science ®Google Scholar
• Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature. 2000;406:747.
   PubMed Web of Science ®Google Scholar
• den Hollander P, Savage MI, Brown PH. Targeted therapy for breast cancer prevention. Front Oncol. 2013;3:250.
   PubMedGoogle Scholar
• Wiley SR, Schooley K, Smolak PJ, et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity. 1995;3:673–682.
   PubMed Web of Science ®Google Scholar
• Allen JE, El-Deiry WS. Regulation of the human TRAIL gene. Cancer Biol Ther. 2012;13:1143–1151.
   PubMed Web of Science ®Google Scholar
• Walczak H, Miller RE, Ariail K, et al. Tumoricidal activity of tumor necrosis factor-related apoptosis – inducing ligand in vivo. Nat Med. 1999;5:157.
   PubMed Web of Science ®Google Scholar
• Lemke J, Von Karstedt S, Zinngrebe J, et al. Getting TRAIL back on track for cancer therapy. Cell Death Differ. 2014;21:1350.
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang B. TRAIL resistance of breast cancer cells is associated with constitutive endocytosis of death receptors 4 and 5. Mol Cancer Res. 2008;6:1861–1871.
   PubMed Web of Science ®Google Scholar
• Han MA, Lee DH, Woo SM, et al. Galangin sensitizes TRAIL-induced apoptosis through down-regulation of anti-apoptotic proteins in renal carcinoma Caki cells. Sci Rep. 2016;6:18642.
   PubMed Web of Science ®Google Scholar
• Ganta C, Ayuzawa R, Rachakatla R, et al. Rat umbilical cord stem cells completely abolish rat mammary carcinomas with no evidence of metastasis or recurrence 100 days post-tumor cell inoculation. Cancer Res. 2009;69:1815–1820.
   PubMed Web of Science ®Google Scholar
• Zhang T, Lee YW, Rui YF, et al. Bone marrow-derived mesenchymal stem cells promote growth and angiogenesis of breast and prostate tumors. Stem Cell Res Ther. 2013;4:70.
   PubMed Web of Science ®Google Scholar
• da Silva Meirelles L, Chagastelles PC, Nardi NB. Mesenchymal stem cells reside in virtually all post-natal organs and tissues. J Cell Sci. 2006;119:2204–2213.
   PubMed Web of Science ®Google Scholar
• Fukuchi Y, Nakajima H, Sugiyama D, et al. Human placenta-derived cells have mesenchymal stem/progenitor cell potential. Stem Cells. 2004;22:649–658.
   PubMed Web of Science ®Google Scholar
• Li X, Ling W, Pennisi A, et al. Human placenta-derived adherent cells prevent bone loss, stimulate bone formation, and suppress growth of multiple myeloma in bone. Stem Cells. 2011;29:263–273.
   PubMed Web of Science ®Google Scholar
• Allen H, Shraga-Heled N, Blumenfeld M, et al. Human placental-derived adherent stromal cells co-induced with TNF-α and IFN-γ inhibit triple-negative breast cancer in nude mouse xenograft models. Sci Rep. 2018;8:670.
   PubMed Web of Science ®Google Scholar
• Grisendi G, Bussolari R, Cafarelli L, et al. Adipose-derived mesenchymal stem cells as stable source of tumor necrosis factor-related apoptosis-inducing ligand delivery for cancer therapy. Cancer Res. 2010;70:3718–3729.
   PubMed Web of Science ®Google Scholar
• Sasportas LS, Kasmieh R, Wakimoto H, et al. Assessment of therapeutic efficacy and fate of engineered human mesenchymal stem cells for cancer therapy. Proc Natl Acad Sci U S A. 2009;106:4822–4827.
   PubMed Web of Science ®Google Scholar
• Marini I, Siegemund M, Hutt M, et al. Antitumor activity of a mesenchymal stem cell line stably secreting a tumor-targeted TNF-related apoptosis-inducing ligand fusion protein. Front Immunol. 2017;8:536.
   PubMed Web of Science ®Google Scholar
• Attar R, Sajjad F, Qureshi MZ, et al. TRAIL based therapy: overview of mesenchymal stem cell based delivery and miRNA controlled expression of TRAIL. Asian Pac J Cancer Prev. 2014;15:5495–5497.
   Google Scholar
• Jacquemin G, Shirley S, Micheau O. Combining naturally occurring polyphenols with TNF-related apoptosis-inducing ligand: a promising approach to kill resistant cancer cells? Cell Mol Life Sci. 2010;67:3115–3130.
   PubMed Web of Science ®Google Scholar
• Trivedi R, Mishra DP. Trailing TRAIL resistance: novel targets for TRAIL sensitization in cancer cells. Front Oncol. 2015;5:69.
   PubMed Web of Science ®Google Scholar
• Bar-Sela G, Epelbaum R, Schaffer M. Curcumin as an anti-cancer agent: review of the gap between basic and clinical applications. CMC. 2010;17:190–197.
   PubMed Web of Science ®Google Scholar
• Jung EM, Park J-W, Choi KS, et al. Curcumin sensitizes tumor necrosis factor-related apoptosis-inducing ligand (TRAIL)-mediated apoptosis through CHOP-independent DR5 upregulation. Carcinogenesis. 2006;27:2008–2017.
   PubMed Web of Science ®Google Scholar
• Liu J, Chen S, Lv L, et al. Recent progress in studying curcumin and its nano-preparations for cancer therapy. CPD. 2013;19:1974–1993.
   Google Scholar
• Montalbán MG, Coburn JM, Lozano-Pérez AA, et al. Production of curcumin-loaded silk fibroin nanoparticles for cancer therapy. Nanomaterials. 2018;8:126.
   Web of Science ®Google Scholar
• Yang DH, Kim HJ, Park K, et al. Preparation of poly-l-lysine-based nanoparticles with pH-sensitive release of curcumin for targeted imaging and therapy of liver cancer in vitro and in vivo. Drug Deliv. 2018;25:950–960.
   PubMed Web of Science ®Google Scholar
• Azandeh SS, Abbaspour M, Khodadadi A, et al. Anticancer activity of curcumin-loaded PLGA nanoparticles on PC3 prostate cancer cells. Iran J Pharm Res. 2017;16:868.
   PubMed Web of Science ®Google Scholar
• Tabatabaei Mirakabad FS, Akbarzadeh A, Milani M, et al. A comparison between the cytotoxic effects of pure curcumin and curcumin-loaded PLGA-PEG nanoparticles on the MCF-7 human breast cancer cell line. Artif Cells Nanomed Biotechnol. 2016;44:423–430.
   PubMed Web of Science ®Google Scholar
• Yang X, Li Z, Wu Q, et al. TRAIL and curcumin codelivery nanoparticles enhance TRAIL-induced apoptosis through upregulation of death receptors. Drug Deliv. 2017;24:1526–1536.
   PubMed Web of Science ®Google Scholar
• Secchiero P, Melloni E, Corallini F, et al. Tumor necrosis factor-related apoptosis-inducing ligand promotes migration of human bone marrow multipotent stromal cells. Stem Cells. 2008;26:2955–2963.
   PubMed Web of Science ®Google Scholar
• Khorashadizadeh M, Soleimani M, Khanahmad H, et al. Bypassing the need for pre-sensitization of cancer cells for anticancer TRAIL therapy with secretion of novel cell penetrable form of Smac from hA-MSCs as cellular delivery vehicle. Tumor Biol. 2015;36:4213–4221.
   PubMedGoogle Scholar